An in vitro whole genome CRISPR/Cas9 screen in leukemia cell lines revealed EZH2 (enhancer of zest homolog 2) as a negative regulator of MHC-I, the master regulator of MHC-I transcription NRLC5 (nucleotide-binding domain and leucine-rich repeat caspase recruitment domain-containing 5), and TAP expression [33]. This evidence concerns the gene EZH2 and leukemia.